CMS Open Payments · Program Year 2024
Piramal Critical Care
Piramal Critical Care reported $111,824.13 across General Payments, Research, and Ownership to 445 physicians and teaching hospitals across 445 transactions.
- $111.8K
- All-tracks total
- 445
- Transactions
- 445
- Recipients
- +$40.3K
- General Payments vs PY2023
Piramal Critical Care reported $111,824.13 across all CMS Open Payments tracks (General + Research + Ownership) to 445 physicians and teaching hospitals in Program Year 2024 - ranking #1153 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $111,824.13, averaging $251.29 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer piramal-critical-care Piramal Critical Care
$111.8K · #1153/1,925 · 0.0% industry · PY2024
- TOT $111.8K
- RANK #1153
- SHARE 0.0%
- TXN 445
- RCP 445
- CAT 4
- GEN $111.8K
- ΔGEN +$40.3K
- TOP1 28.2%
- PY 2024
Volume peers
Nearest volume peer: Semler Scientific, Inc. ($112.0K)
Piramal Critical Care sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Piramal Critical Care's CMS-reported General Payments increased by $40.3K (+56.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PIRAMAL CRITICAL CAREPY2023: PIRAMAL CRITICAL CAREPY2024: PIRAMAL CRITICAL CARE. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $71,537.34
- PY2024
- $111,824.13
What the Data Shows for Piramal Critical Care
Averaging $251.29 per transaction and $251.29 per recipient, Piramal Critical Care's Program Year 2024 total comes to $111,824.13 across 445 transactions and 445 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1153 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $85.6K, accounting for 76.5% of this company's General Payments and 31 transactions.
General Payment Breakdown by Type
Piramal Critical Care made 4 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $85.6K, 76.5% of General Payments.
Piramal Critical Care reports 4 general-payment categories - the top three are Compensation for Services Other Than Consulting (76.5%), Food and Beverage (13.2%), and Travel and Lodging (10.0%). The remaining 1 category make up 0.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Piramal Critical Care divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $85.6K | 31 | 76.5% |
| Food and Beverage | $14.8K | 339 | 13.2% |
| Travel and Lodging | $11.2K | 74 | 10.0% |
| Consulting Fee | $225.00 | 1 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $76,477.62 (68.4%) of $111,824.13 in this company's General Payments records across 245 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Piramal Critical Care
The five named recipients with the highest reported General Payments from this company
- 1
Zachary W Bohart
$31,537.23 across 56 reported transactions
- 2
Christopher Cronsell
$17,715.93 across 30 reported transactions
- 3
Robert Friedman
$10,870.31 across 24 reported transactions
- 4
Joseph Urquidez
$10,012.86 across 12 reported transactions
- 5
Ravi E Kasi
$6,341.29 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Piramal Critical Care's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Piramal Critical Care.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Piramal Critical Care.
Showing 6 of 1,924 companies with CMS-reported payment data.
Rivanna Medical, Inc
L&K Spine Inc
Bone Support Ab
Substrate HD
Medical Microinstruments, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.